Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22912746 | 0.85 | ADORA2B (0.34) | ADORA2BATMPAK1 | |
| SCHEMBL22912744 | 0.83 | ADORA2B (0.34) | ADORA2BATM | |
| SCHEMBL22912742 | 0.82 | GAA (0.37) | ADORA2B | |
| SCHEMBL29601214 | 0.81 | SLC29A1 (0.43) | — | |
| SCHEMBL22912677 | 0.76 | ADORA2B (0.39) | ADORA2B | |
| SCHEMBL29601167 | 0.76 | ALDH1A1 (0.36) | PAK1 | |
| SCHEMBL22912741 | 0.71 | SLC29A1 (0.36) | — | |
| SCHEMBL22912743 | 0.68 | SLC29A1 (0.43) | — | |
| SCHEMBL28669450 | 0.66 | ADORA2A (0.40) | ADORA2B | |
| SCHEMBL29601775 | 0.66 | ADORA2B (0.40) | ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220251085-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3997089-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | University Of Virginia Patent Foundation (US) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251085-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | DDB1, HSPBP1, ATIC | ADORA2B 987/4885ATM 2560/4885PAK1 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.